论文部分内容阅读
用抗胸腺细胞球蛋白(ATG)治疗严重再生障碍性贫血(再障),能使约半数患者恢复造血。由于ATG兼有免疫抑制和免疫刺激作用,故其作用机理仍然不明。作者通过测定淋巴细胞表型和淋巴因子对22例成人再障患者进行了研究。ATG治疗后2—4个月,T淋巴细胞以及辅助和抑制淋巴细胞亚群的数量无明显变化,淋巴细胞总数或辅助/抑制淋巴细胞之比与疗效之间无相关关系。治疗前,受检的15/22
Treatment of severe aplastic anemia (AA) with anti-thymocyte globulin (ATG) can restore hematopoiesis in about half of patients. Because ATG both immunosuppressive and immune stimulating effect, so the mechanism of action is still unknown. The authors studied 22 adult patients with aplastic anemia by measuring lymphocyte phenotypes and lymphokines. At 2-4 months after ATG treatment, there was no significant change in the number of T lymphocytes and the number of helper and suppressor lymphocyte subsets. There was no correlation between the number of lymphocytes and the ratio of adjuvant / suppressed lymphocytes and efficacy. Before treatment, the subjects examined 15/22